neuroblastoma market research, neuroblastoma market drivers, neuroblastoma market size, neuroblastoma market insights, neuroblastoma market outlook, neuroblastoma market scope
What are the latest figures on the neuroblastoma market’s size and projected CAGR?
The neuroblastoma market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to increase in neuroblastoma prevalence, increase in research and development for pediatric neuroblastoma treatments, increase in the incidence of childhood cancer and growing funding and support from government.
The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing government funding, increasing incidence of the disease, growing focus on early detection, increasing prevalence of genetic mutations, and increasing understanding and research advancements. Major trends in the forecast period include development of drugs targeting specific molecular pathways, innovations in non-invasive imaging technologies, advances in gene-editing technologies, increasing focus on personalized treatment, the development of radiolabeled compounds.
Get Your Free Sample of The Global Neuroblastoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp
Which Market drivers have played a significant role in driving the neuroblastoma market?
The increase in the incidence of childhood cancer is expected to propel the growth of the neuroblastoma market going forward. Childhood cancer is a collection of cancers that primarily affect children and adolescents, commonly targeting organs such as the brain, blood, and bones and necessitating specialized treatment approaches. The rise in the incidence of childhood cancer is attributed to factors such as improved diagnostic techniques, better awareness, environmental exposures, genetic predispositions, and advances in medical research. Neuroblastoma treatment provides targeted therapies for childhood cancer, enabling early and effective intervention that lowers the risk of recurrence and improves outcomes for young patients. For instance, in May 2024, according to the American Cancer Society, a US-based professional organization company, in 2024, approximately 9,620 children under the age of 15 in the United States are projected to be diagnosed with cancer, an increase from 5,290 cases in 2023. Therefore, the increase in the incidence of childhood cancer is driving the growth of the neuroblastoma market.
What are the key segments within the neuroblastoma market?
The neuroblastoma market covered in this report is segmented –
1) By Product Types: Tablets, Vaccines, Other Product Types
2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types
3) By Distribution Channel: Online, Offline
4) By End-User: Hospitals, Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/neuroblastoma–global-market-report
Which key players are shaping the neuroblastoma market?
Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
Which key trends are expected to influence the neuroblastoma market in the coming years?
Major companies operating in the neuroblastoma market are focusing on developing advanced therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to target and treat cancer cells more effectively and safely specifically. A humanized anti-GD2 monoclonal antibody is engineered to target the GD2 molecule on cancer cells with reduced immune rejection by incorporating human components. For instance, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital. This antibody is designed to treat newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. Under the terms of the agreement, Renaissance has secured exclusive rights to develop, manufacture, and commercialize Hu14.18 across key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.
How do regional factors impact the neuroblastoma market, and which region is the largest contributor?
North America was the largest region in the neuroblastoma market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Neuroblastoma Market Report 2025 Offer?
The neuroblastoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Neuroblastoma is a type of cancer that primarily affects children and arises from immature nerve cells called neuroblasts. It commonly develops in the adrenal glands, located on top of the kidneys, and occurs in other areas of the abdomen, chest, neck, or pelvis. The cancer can cause symptoms such as abdominal pain, swelling, fatigue, and sometimes bone pain or lumps.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20901
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
